Cancer Therapeutics CRC CEO

Mr Brett Carter

New Venture Partner

_DSC6700

In December 2019, Brett stepped down from the role of CEO of Cancer Therapeutics CRC to focus on leading the organisation’s transition plans.  Prior to this Brett was appointed to the role of Chief Operating Office in March 2017, and led the organisation in the role of Chief Executive Officer between March 2018 and December 2019.

He has more than 20 years of pharmaceutical industry experience with broad exposure across the medicine discovery, development and commercialisation lifecycle, having held roles in research & development, manufacturing & supply and business development.

Brett worked at GSK for 11 years, initially in Product Development and later in Business Development, where he led worldwide licensing, acquisition and venture capital backed business development transactions. Prior to joining GSK, Brett worked as a chemist and as a management consultant. He is a former Chair of the Global Health Investment Fund Limited Partner Advisory Committee, and has a BSc in Applied Chemistry from RMIT University Melbourne, an MBA from London Business School and a graduate from the of the Australian Institute of Company Directors.